UK-based Gyroscope Therapeutics Ltd has appointed Soraya Bekkali to the dual role of chief executive and chief medical officer to oversee its experimental gene therapies for retinal diseases. Dr Bekkali joins from France-based Lysogene SA, which is developing gene therapies for central nervous system disorders. She also led the ophthalmology business unit at Sanofi SA.
Dr Bekkali received her medical degree from the Paris Medical School and began her career as a clinical pharmacologist in academia before joining the pharmaceutical industry.
Gyroscope announced the appointment on 20 September 2017.
Copyright 2017 Evernow Publishing Ltd